Literature DB >> 7685119

Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.

S Li1, M Rodrigues, D Rodriguez, J R Rodriguez, M Esteban, P Palese, R S Nussenzweig, F Zavala.   

Abstract

Live vectors expressing foreign antigens have been used to induce immunity against several pathogens. However, for the virulent rodent malaria parasite Plasmodium yoelii, the use of recombinant vaccinia virus, pseudorabies virus, or Salmonella, expressing the circumsporozoite protein of this parasite, failed to induce protection. We generated a recombinant influenza virus expressing an epitope from the circumsporozoite protein of P. yoelii known to be recognized by CD8+ T cells and demonstrated that this vector induced class I major histocompatibility complex-restricted cytotoxic T cells against this foreign epitope. Immunization of mice with this recombinant influenza virus, followed by a recombinant vaccinia virus expressing the entire circumsporozoite protein, induced protective immunity against sporozoite-induced malaria. The sequence of immunization appears to be crucial, since a primer injection with recombinant vaccinia virus, followed by a booster injection with recombinant influenza virus, failed to induce protection. The protection induced by immunization with these recombinant viruses is mostly mediated by CD8+ T cells, as treatment of mice with anti-CD8 monoclonal antibody abolishes the anti-malarial immunity. The use of different live vectors for primer and booster injections has a synergistic effect on the immune response and might represent an effective general strategy for eliciting protective immune responses to key antigens of microbial pathogens.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685119      PMCID: PMC46686          DOI: 10.1073/pnas.90.11.5214

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

2.  CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites.

Authors:  W R Weiss; M Sedegah; R L Beaudoin; L H Miller; M F Good
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

3.  Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites.

Authors:  L Schofield; J Villaquiran; A Ferreira; H Schellekens; R Nussenzweig; V Nussenzweig
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

4.  Complete sequence analysis shows that the hemagglutinins of the H0 and H2 subtypes of human influenza virus are closely related.

Authors:  A L Hiti; A R Davis; D P Nayak
Journal:  Virology       Date:  1981-05       Impact factor: 3.616

5.  Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle.

Authors:  M Mackett; T Yilma; J K Rose; B Moss
Journal:  Science       Date:  1985-01-25       Impact factor: 47.728

6.  Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters.

Authors:  G L Smith; B R Murphy; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

7.  Recombinant pseudorabies virus carrying a plasmodium gene: herpesvirus as a new live viral vector for inducing T- and B-cell immunity.

Authors:  M Sedegah; C H Chiang; W R Weiss; S Mellouk; M D Cochran; R A Houghten; R L Beaudoin; D Smith; S L Hoffman
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

8.  Expression of rabies virus glycoprotein from a recombinant vaccinia virus.

Authors:  M P Kieny; R Lathe; R Drillien; D Spehner; S Skory; D Schmitt; T Wiktor; H Koprowski; J P Lecocq
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

9.  Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells.

Authors:  J R Bennink; J W Yewdell; G L Smith; C Moller; B Moss
Journal:  Nature       Date:  1984 Oct 11-17       Impact factor: 49.962

10.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.

Authors:  S Chakrabarti; K Brechling; B Moss
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

View more
  82 in total

1.  A subdominant CD8(+) cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture.

Authors:  E D Franke; A Sette; J Sacci; S Southwood; G Corradin; S L Hoffman
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

2.  Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen.

Authors:  O Bruña-Romero; G González-Aseguinolaza; J C Hafalla; M Tsuji; R S Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

3.  Generation of replication-competent recombinant influenza A viruses carrying a reporter gene harbored in the neuraminidase segment.

Authors:  Feng Li; Liqiang Feng; Weiqi Pan; Zhenyuan Dong; Chufang Li; Caijun Sun; Ling Chen
Journal:  J Virol       Date:  2010-09-08       Impact factor: 5.103

4.  CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.

Authors:  Adriano F S Araújo; Bruna C G de Alencar; José Ronnie C Vasconcelos; Meire I Hiyane; Cláudio R F Marinho; Marcus L O Penido; Silvia B Boscardin; Daniel F Hoft; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 5.  Building better T-cell-inducing malaria vaccines.

Authors:  Stephen M Todryk; Michael Walther
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

6.  A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII.

Authors:  Takayuki Shiratsuchi; Urvashi Rai; Izumi Kaneko; Min Zhang; Shiroh Iwanaga; Masao Yuda; Moriya Tsuji
Journal:  Vaccine       Date:  2017-10-28       Impact factor: 3.641

7.  Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.

Authors:  O J A E Ophorst; K Radosević; M J E Havenga; M G Pau; L Holterman; B Berkhout; J Goudsmit; M Tsuji
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

8.  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.

Authors:  T Muster; B Ferko; A Klima; M Purtscher; A Trkola; P Schulz; A Grassauer; O G Engelhardt; A García-Sástre; P Palese
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Immunogenicity of the Plasmodium falciparum glutamate-rich protein expressed by vaccinia virus.

Authors:  M Theisen; G Cox; B Høgh; S Jepsen; J Vuust
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

10.  Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii.

Authors:  Gloria González-Aseguinolaza; Yurie Nakaya; Alberto Molano; Edward Dy; Mariano Esteban; Dolores Rodríguez; Juan Ramón Rodríguez; Peter Palese; Adolfo García-Sastre; Ruth S Nussenzweig
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.